Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

http://www.wikidata.org/entity/Q38524435

about

Glucagon and heart in type 2 diabetes: new perspectives Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Cardiovascular safety of anti-diabetic drugs Current perspectives on cardiovascular outcome trials in diabetes Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects Update on the treatment of type 2 diabetes mellitus Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory.Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study.The regulatory role of DPP4 in atherosclerotic disease.DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.Puerarin Improves Diabetic Aorta Injury by Inhibiting NADPH Oxidase-Derived Oxidative Stress in STZ-Induced Diabetic Rats Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.An overview of new GLP-1 receptor agonists for type 2 diabetes.Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.Cardiometabolic crosstalk in obesity-associated arterial hypertension.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Implications of the EMPA-REG Trial for Clinical Care and Research.Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.Cardiovascular effects of anti-diabetes drugs.Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes.Investigational glucagon-like peptide-1 agonists for the treatment of obesity.Progressing From Metformin to Sulfonylureas or Meglitinides.Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options.Coronary microvascular dysfunction in diabetes mellitus.Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus.Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan.Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints.

P2860

Q26738580-8381DC8F-985E-4433-877D-62AE4E798A3B Q26740253-838BA258-D7F9-435C-A46E-E79A392FA5A3 Q26741082-72FA29D2-38CC-41C2-BCD1-AB6FA6B6399F Q28066006-D2D34A7A-2910-41F2-ABD8-0A12BD85DC6B Q28072765-266061A8-97AE-4901-9B3E-60C3E6EC739F Q28073342-4872BF78-09F5-4E91-A01A-0CA39FC4DA2E Q30238519-2E763A12-C5FB-4348-A4DB-0E676346A5B3 Q30249371-F55D4150-23A9-4A01-BA51-0339F1FECBF9 Q33625568-3BA0F957-051E-4E87-9FAC-514919F04A50 Q33696974-D6E1653C-9EE2-4773-A1A6-838355EF203C Q33700894-C2485250-4A58-4C99-B892-E17532790F09 Q33727891-CCC76FF6-BCB2-48A4-916B-7593D7D00BFB Q33732583-2B1525CA-C0C7-4798-AD72-6B1D1D42DDF5 Q33805518-EAB9D244-1F55-4BAD-AF28-DCE20B61E950 Q36338382-9380A84D-9C64-433E-9A6F-C3C9F665FBD4 Q36531636-5CADC856-22D4-4F11-8383-76793398930F Q37011769-44AB6528-8E71-4C87-BC33-879E1936E3BA Q37620904-80E277CB-C6EA-4C48-BA2F-B129EF4D50F9 Q38599145-8626855D-5E07-4D65-968E-883350CEA765 Q38639922-8CB35F59-6BB2-4452-AC11-94AF49460F11 Q38662950-6DA901FC-A65B-4CCD-AB2C-5D234EB0FFDE Q38683079-7A8E9919-A15D-4BB6-B675-4497A251E9BC Q38702260-EEE75132-0347-4F80-B548-5FB1C716E5DF Q38767511-3D8C4EAF-F2F0-442D-B578-B2BCFCD1F6F7 Q38783203-4497BE0D-A961-4698-A6CB-6DB52320200A Q38798623-1D3BB769-B4A1-4E2E-910F-A8E1C999EDA1 Q38827756-FF98B493-F7D6-44FA-9122-0049EB8286B7 Q38857056-739E3E85-A818-47A8-95D6-E1929E958739 Q38877104-DB8B8254-7D8B-47F9-A02A-42822848CAAF Q38937735-58F4C6A9-D9DF-4D02-BC9A-6BCE7EDA4A7C Q38952882-B8B22253-638D-4D73-B10A-BC44D3A2CC1E Q39226058-A5F0A221-B431-4F1A-BE4C-BA9F3E3EF590 Q39245449-F33A2646-8682-4C9E-9A5A-0BE451A92025 Q39393549-1BFD7114-DC47-4F50-93BB-53F581079133 Q39409421-F661E873-8DAC-401D-943D-8B3A987ED9E3 Q39418202-EB973F6D-F637-4685-9863-AFB9CD43BB81 Q39735496-1FAD56B7-B8DC-4453-A52D-C0949D22DD59 Q40113914-806279AC-ABF6-4764-B5B9-34E78FF28648 Q40808660-FCC59763-D691-4CE8-B705-EF5E59DB11F0 Q46078298-E562B5DC-642D-4A17-9AB8-16AD5C3CCF3D

P2860

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

http://www.wikidata.org/entity/Q38524435

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

@en

type

label

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

@en

prefLabel

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

@en

P1433

Q38524435-6704D356-7D3D-47A7-B518-F4DFADCB5297

P1476

Q38524435-3B97958D-BD6E-434E-B7A3-DDF949AA3EB8

P2093

Q38524435-95772290-9B32-48BE-BB63-FA93FE613F0D

P2860

Q38524435-010DEA82-4005-4BE9-A5B1-8057B9AE723C

Q38524435-02C0A5AD-BC65-4537-8906-ECAC2837B2EC

Q38524435-048C4BD6-1A03-414D-95CF-35CEE43B1BE2

Q38524435-05B6654A-BA70-4B88-9921-B64F879E78E1

Q38524435-06E9471A-CD19-40EE-9FEA-F2DBDFBF38FB

Q38524435-0721E1E5-4EC1-47C5-8E61-1EF55B2E8220

Q38524435-072CFFF9-7822-4F02-8EBD-4A2C912EB3C9

Q38524435-08408357-8B57-4E53-834F-C18F00AAF4C7

Q38524435-088CFA23-5201-4D6D-AEC1-0CB3781E3222

Q38524435-088D3BE2-443B-4936-B2CA-84009439F00B

P304

Q38524435-10AEA97A-146B-49A8-8CCA-C39AA665E757

P31

Q38524435-140C47AE-9E1B-4356-8FB3-14987F1D4EB2

P356

Q38524435-301DC627-2156-4D98-9F1A-DFE27E64C61F

P433

Q38524435-34896EF1-F900-4E35-BC5A-E5F75AF5E08B

P478

Q38524435-E51596D3-92E9-4C53-B0CE-E1C369372E2F

P50

Q38524435-7A308431-1FC2-45E7-B74F-50CE696A057B

P577

Q38524435-669704B2-CCD2-4BFC-B1A7-5D2FA13047D8

P5875

Q38524435-01F0E02E-4D47-4EEC-91E0-07B66C4EA1EC

P698

Q38524435-158B9FA3-643C-486D-8548-1E6AB90053FE

P921

Q38524435-A2BB0AE0-778E-4D4F-940D-CF9DDB37C3A2

Q38524435-C0C13792-AABA-45F1-97AF-2328E3BC1814

P356

P1433

European Heart Journal

P1476

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

@en

P2093

Ele Ferrannini

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease

Residual macrovascular risk in 2013: what have we learned?

P304

2288-2296

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHV239

http://www.w3.org/2001/XMLSchema#string

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Ralph A DeFronzo

P577

2015-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278042617

http://www.w3.org/2001/XMLSchema#string

P698

26063450

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

cardiovascular disease